Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
It is the first monoclonal antibody drug for use in any animal species
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The stability is led by healthy demand in the domestic and emerging markets
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Subscribe To Our Newsletter & Stay Updated
